(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.78%.
Orchestra Biomed Holdings's earnings in 2025 is -$66,316,000.On average, 5 Wall Street analysts forecast OBIO's earnings for 2025 to be -$76,701,649, with the lowest OBIO earnings forecast at -$79,306,900, and the highest OBIO earnings forecast at -$72,027,523. On average, 5 Wall Street analysts forecast OBIO's earnings for 2026 to be -$65,667,646, with the lowest OBIO earnings forecast at -$69,345,647, and the highest OBIO earnings forecast at -$63,598,770.
In 2027, OBIO is forecast to generate -$59,001,268 in earnings, with the lowest earnings forecast at -$64,365,020 and the highest earnings forecast at -$53,637,517.